X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Derazantinib
Therapeutic Area: Oncology Product Name: BAL087
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 10, 2021
Details:
Clinical proof of concept achieved for derazantinib monotherapy in FGFR2 gene fusion-positive iCCA. Derazantinib has shown a well manageable safety profile.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Camidanlumab tesirine
Therapeutic Area: Oncology Product Name: Cami
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 04, 2021
Details:
Camidanlumab tesirine (Cami, formerly ADCT-301) is an antibody drug conjugate (ADC) comprised of a monoclonal antibody that binds to CD25 (HuMax®-TAC, licensed from Genmab A/S), conjugated to the pyrrolobenzodiazepine (PBD) dimer payload, tesirine.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Efineptakin alfa,Atezolizumab
Therapeutic Area: Oncology Product Name: NT-I7
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: NeoImmuneTech
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 21, 2020
Details:
This new master agreement will focus initially on a Phase 2 trial in previously untreated, PD-L1-expressing, locally advanced or metastatic non-small cell lung cancer patients, with the goal to evaluate anti-tumor efficacy and safety of the NT-I7 and atezolizumab combination.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Tenalisib
Therapeutic Area: Oncology Product Name: RP6530
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Curon Biopharmaceutical
Deal Size: $149.5 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 12, 2020
Details:
Curon obtains the exclusive development and commercialization rights of Tenalisib for Greater China across all oncology indications, and will lead the clinical development in that territory.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
